TEVA - Teva Pharmaceutical Industries Limited
| Previous close | 17.56 |
| Open | 17.53 |
| Bid | 17.25 x 1400 |
| Ask | 17.26 x 1400 |
| Day's range | 16.97 - 17.57 |
| 52-week range | 10.85 - 33.82 |
| Volume | 5,644,557 |
| Avg. volume | 12,653,820 |
| Market cap | 17.536B |
| Beta | 1.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -16.26 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 19.29 |
- Bloomberg Video•16 days ago
Teva Chairman Says Tariffs Won't Have a Major Impact on Biotech
Apr.09 -- Teva Chairman Sol Barer discusses the impact he believes potential tariffs would have on the biotech industry. He speaks with Bloomberg's Vonnie Quinn and Shery Ahn on "Bloomberg Markets."
- Reuters•yesterday
Express Scripts targets Amgen, Lilly migraine drugs in pricing shift
The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc (AMGN.O), Eli Lilly and Co (LLY.N) and other makers of new migraine medicines to try and fix it. Express Scripts (ESRX.O) told Reuters it is pressing them to forego the usual strategy of setting a high U.S. list price, then lowering the cost for health plans through hefty rebates. It is also seeking a refund if the drugs don't work within a defined timeframe.The shift could help Express Scripts and other pharmacy benefits managers (PBMs) bring prices down, and deflect growing criticism of their role as "middlemen" in the drug supply chain.
- Reuters - UK Focus•yesterday
FOCUS-Express Scripts targets Amgen, Lilly migraine drugs in pricing shift
The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc, Eli Lilly and Co and other makers of new migraine medicines to try and fix it. Express Scripts told Reuters it is pressing them to forego the usual strategy of setting a high U.S. list price, then lowering the cost for health plans through hefty rebates. The shift could help Express Scripts and other pharmacy benefits managers (PBMs) bring prices down, and deflect growing criticism of their role as "middlemen" in the drug supply chain.
- Reuters•yesterday
Express Scripts targets new migraine drugs to change U.S. pricing dynamic
The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc and other makers of new migraine medicines to try and fix it. Express Scripts told Reuters it is pressing them to forego the usual strategy of setting a high U.S. list price, then lowering the cost for health plans through hefty rebates. It is also seeking a refund if the drugs don't work within a defined timeframe.The shift could help Express Scripts and other pharmacy benefits managers (PBMs) bring prices down, and deflect growing criticism of their role as "middlemen" in the drug supply chain.
- Market Realist•2 days ago
Analysts’ Recommendations for Eli Lilly & Co. on April 20
Eli Lilly & Co. (LLY) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues during 4Q17. The company reported EPS of $1.14 on revenues of ~$6.2 billion, compared to the estimated EPS of $1.07 on revenues of ~$5.9 billion. Analysts expect the company to report EPS of $1.14 on revenues of $5.5 billion during 1Q18.
- Business Wire•2 days ago
Teva to Report First Quarter 2018 Financial Results on May 3, 2018
Teva Pharmaceutical Industries Ltd. announced today that it will release its first quarter 2018 financial results on Thursday, May 3, 2018 at 7:00 a.m. ET.
- Market Realist•6 days ago
Jazz Pharmaceuticals’ 2018 Guidance and Analyst Recommendations
Jazz Pharmaceuticals (JAZZ) estimates that in fiscal 2018, its net revenue will be $1.86 billion–$1.93 billion. Its estimated GAAP (generally accepted accounting principles) gross margin is 93% for 2018.
- Business Wire•6 days ago
Teva and the Procter & Gamble Company Have Agreed to Terminate the PGT Healthcare Partnership
Teva Pharmaceutical Industries [NYSE and TASE: TEVA] has announced that Teva and the Procter & Gamble Company [NYSE: PG] have agreed to terminate the PGT Healthcare partnership that the two companies established in 2011 to market OTC (Over The Counter) medicines. No significant (material) net financial transfer between Teva and P&G will result from the dissolution. PGT Healthcare has grown into a significant presence in over 50 countries, mainly in Europe and Asia, using market-leading brands such as Vick’s and ratiopharm.
- Market Realist•7 days ago
Jazz Pharmaceuticals’ Xyrem, Erwinase, and Defitelio
In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $312.5 million compared to $291 million in 4Q16. In fiscal 2017, Xyrem reported revenues of $1.2 billion compared to $1.1 billion in 2016, which reflected a 7% growth on a YoY basis. Xyrem is used for the treatment of cataplexy in narcolepsy and excessive daytime sleepiness in narcolepsy.
- Market Realist•7 days ago
Jazz Pharmaceuticals: How It’s Positioned before 1Q18
In 4Q17, Jazz Pharmaceuticals (JAZZ) generated revenues of $436.4 million compared to $396.6 in 4Q16, which reflected a 10% growth on a YoY (year-over-year) basis and a 6% growth quarter-over-quarter.
- Market Realist•7 days ago
Novartis’s 1Q18 Estimates: Expectations for Sandoz
Sandoz, the generics arm of Novartis (NVS), includes pharmaceuticals and biotechnological active substances in its portfolio. Sandoz is expected to report growth in operating revenue in 1Q18.
- Business Wire•8 days ago
Teva to Present New Data Across Multiple Therapeutic Areas at 70th Annual Meeting of the American Academy of Neurology
Teva Pharmaceutical Industries Ltd. today announced 38 scientific abstracts across five difficult-to-treat disorders of the central nervous system will be presented at the 70th Annual Meeting of the American Academy of Neurology in Los Angeles from April 21-27, 2018.
Market Realist•8 days agoAbbVie’s Imbruvica in 4Q17 and Fiscal 2017
AbbVie’s (ABBV) Imbruvica generated revenue of $708 million in 4Q17 and $511 million in 4Q16, reflecting ~39% growth YoY (year-over-year) and ~3% growth quarter-over-quarter. In 4Q17, in US and international markets, Imbruvica reported revenue of $585 million and $123 million, respectively, reflecting ~35.3% and ~57.8% growth YoY.
- Reuters•10 days ago
Israeli unions warn Teva Pharm over plan to close Ashdod plant
Israel's main labour federation intends to strike or take legal action against Teva Pharmaceutical Industries (TEVA.TA) if the drugmaker does not suspend a decision to close a plant in the port city of Ashdod, it said on Sunday. Debt-laden Teva (TEVA.N), the world's largest generic drugmaker and Israel's biggest company, said last week that it would close the unprofitable plant in March 2019 after failing to find a buyer for the facility. In a letter to Teva's management, the Histadrut federation said the company's decision was contrary to a previous declaration that it would retain most of its activities in Israel.
Reuters•10 days agoIsraeli unions warn Teva Pharm over plan to close Ashdod plant
Israel's main labor federation intends to take labor or legal action against Teva Pharmaceutical Industries (TEVA.TA) if the drugmaker does not suspend a decision to close a plant in the Israeli port city of Ashdod, it said on Sunday. Debt-laden Teva (TEVA.N), the world's largest generic drugmaker and Israel's biggest company, said last week that it would close the unprofitable plant in March 2019 after failing to find a buyer for the facility. In a letter to Teva's management, the Histadrut federation said the company's decision was contrary to a prior declaration that it would retain most of its activities in Israel.
- Motley Fool•12 days ago
3 Top Healthcare Stocks to Buy in April
April could be the perfect time to pick up shares in these top healthcare stocks.
Market Realist•12 days agoAlexion to Acquire Wilson Therapeutics for $855 Million
On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced that it has made a public cash offer to Wilson Therapeutics’ shareholders to acquire all of the company’s outstanding shares. Wilson Therapeutics is a Sweden-based biopharmaceuticals firm. The acquisition will advance Alexion’s long-term growth strategy, which consists of advancing and rebuilding its rare disease pipeline. Alexion aims to accelerate the diversification of its product portfolio.
- Bloomberg•14 days ago
Are Drug Prices Too Low?
Generic makers say they may stop making medicines that don’t turn a profit.
Market Realist•15 days agoAnalyst Recommendations for Teva Pharmaceutical in April 2018
In December 2017, the FDA accepted Teva Pharmaceutical Industries’ (TEVA) BLA (Biologics License Application) for fremanezumab for the preventive treatment of migraine. In February 2018, the European Medicines Agency accepted the MAA (Marketing Authorization Application) for fremanezumab for the treatment of adults with episodic and chronic migraine. In January 2018, the FDA approved Teva Pharmaceutical’s Trisenox and tretinoin combination therapy for the treatment of individuals with newly-diagnosed, low-risk APL (acute promyelocytic leukemia) with a presence of PML/RAR alpha gene expression.
- Market Realist•15 days ago
A Look at Teva Pharmaceutical’s Specialty Medicines Segment
In 4Q17, Teva Pharmaceutical Industries’ (TEVA) specialty medicines segment generated revenues of $1.8 billion compared to $2.2 billion in 4Q16. That was a 19% YoY (year-over-year) decline.
Market Realist•15 days agoTeva Pharmaceutical’s Specialty Medicines Segment Performance
In fiscal 2017, Teva Pharmaceutical Industries’ (TEVA) CNS (central nervous system) products generated revenues of $4.4 billion compared to $5.3 billion in 2016. That’s a 16% decline on a YoY (year-over-year) basis.
- Market Realist•16 days ago
Teva Pharmaceutical’s Generic Medicines Segment in 2017
In fiscal 2017, Teva Pharmaceutical Industries’ (TEVA) generic medicines segment reported revenues of $12.3 billion compared to $12 billion in 2016, which was a 2% YoY (year-over-year) growth.
- Market Realist•16 days ago
Teva Pharmaceutical’s Performance in 4Q17 and 2017
In 4Q17, Teva Pharmaceutical Industries (TEVA) reported revenues of $5.5 billion compared to $6.5 billion in 4Q16. That’s a 16% growth on a YoY (year-over-year) basis and a 3% growth on a quarter-over-quarter basis.
Reuters•16 days agoTeva Pharm to close plant in Israel after no buyer found
Debt-laden Teva Pharmaceutical Industries said on Monday it would close an unprofitable plant in the Israeli port city of Ashdod in March 2019 after failing to find a buyer for the facility. Teva, the world's largest generic drugmaker and Israel's biggest company, said in a statement half of the factory's 175 workers would lose their jobs in the coming months with the rest continuing to work until the plant closes. In December, Teva said it would cut 14,000 jobs - 25 percent of its global workforce - and close many plants as part of a restructuring aimed at helping to pay down debts.
- Market Realist•23 days ago
How Did Sandoz Perform in 4Q17 and Fiscal 2017?
How Is Novartis Positioned after 4Q17?
